Patients With Advanced Solid Malignancies clinical trials

Explore recruiting patients with advanced solid malignancies clinical trials.

Recruiting patients with advanced solid malignancies studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Patients With Advanced Solid Malignancies trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Study of NTX-1088 as Monotherapy and Combined with Pembrolizumab

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

PHASE 1/2 STUDY OF PARG INHIBITOR ETX-19477 IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

Spain, France, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA)

Spain, Poland, Italy, Czechia, Hungary

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies

Sweden, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

An Open-label Study to check Safety, Tolerability and medication behaviour of a capsule with AZD6244 in Patients with Advanced Solid Malignancies

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Patients With Advanced Solid Malignancies trials by city

Patients With Advanced Solid Malignancies in Toronto Patients With Advanced Solid Malignancies in Vancouver Patients With Advanced Solid Malignancies in Montreal Patients With Advanced Solid Malignancies in Calgary Patients With Advanced Solid Malignancies in Edmonton Patients With Advanced Solid Malignancies in Ottawa Patients With Advanced Solid Malignancies in Winnipeg Patients With Advanced Solid Malignancies in Quebec City Patients With Advanced Solid Malignancies in Hamilton Patients With Advanced Solid Malignancies in Kitchener Patients With Advanced Solid Malignancies in London Patients With Advanced Solid Malignancies in Halifax Patients With Advanced Solid Malignancies in New York Patients With Advanced Solid Malignancies in Los Angeles Patients With Advanced Solid Malignancies in Chicago Patients With Advanced Solid Malignancies in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease